CRB joins Umoja Biopharma to Celebrate the Beginning of Construction at Development and Manufacturing Site
Aug 30, 2021
Louisville, Colo. – On Monday, August 30, Umoja Biopharma and CRB officially kicked off the construction of a 146,000 square foot development and clinical manufacturing facility. CRB, an international leader in sustainable engineering, architecture, construction, and consulting solutions to the life sciences industry will lead the design and construction of the space for Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies. CRB is applying its ONEsolution™ approach to deliver the innovative project and meet aggressive sustainability goals on schedule and on budget.
Andy Scharenberg, M.D., Umoja Biopharma Co-founder & CEO, and members of the CRB and Umoja project team opened the event with a project tour and overview. Attendees included government and economic development officials, business partners and members of the CRB project team and Umoja Biopharma leadership.
CRB will transform the existing building into 146,000 square feet of highly flexible and scalable manufacturing, laboratory, office, and warehouse space. The project design will focus on features to integrate LEED criteria along with zero carbon emissions to meet the company’s sustainability goals.
CRB’s ONEsolution is a complete approach that takes a project from initial planning through operational readiness. It advances the principles of integrated project delivery, uses proven lean construction tools, and capitalizes on the collaborative expertise of a single design and construction team. The result is improved design, increased productivity, reduced waste and inefficiencies, and lower costs.
The current plan is for Phase 1 to be complete by May 2022 and substantial completion by Fall 2022.
About Umoja Biopharma, Inc
Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient’s immune system in vivo. Founded based on pioneering work performed at Seattle Children’s Research Institute and Purdue University, Umoja’s novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit http://umoja-biopharma.com/.